Clinical trial
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects…
NCT00496626 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00496626 |
|---|---|
| Title | An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) |
| Official title | An Immunogenicity and Safety Study of Quadrivalent HPV (Types 6, 11, 16, 18) Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Papillomavirus Infections |
| Intervention type | Biological |
| Interventions | Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), Comparator: Placebo |
| Enrollment | 600 |
| Start date | Jul 20, 2008 |
| Primary completion | Feb 28, 2009 |
| Completion | Feb 28, 2009 |
| First posted | Jul 4, 2007 |
| Last update posted | Apr 17, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: